ObsEva struck a pact with China’s Yuyuan BioScience Technology to develop and commercialise the fertility drug nolasiban, the Swiss drugmaker has said, as it seeks to inject new life into a medicine that had flopped a trial.
In November last year, ObsEva said it was scrapping a development programme for nolasiban to help women undergoing in-vitro fertilisation after it did not meet its primary endpoint of an increase in ongoing pregnancy.
Under the terms of this new agreement, Yuyuan gets the rights to develop and sell nolasiban in China and will pay for activities to get the medicine registered there, including a Phase 1 study and a Phase 2 Proof-of-Concept study.
Financial terms are not being disclosed for the deal that leaves ObsEva with rights outside China.
ObsEva Chief Executive Ernest Loumaye said there had been a bidding process for nolasiban in China, and that “Yuyuan in particular impressed us with their extensive personal networks, commitment, passion and deep insights in the IVF space.”
Despite nolasiban’s earlier failure, Loumaye said, “I remain convinced that oxytocin antagonists have a role in improving live birth rate following IVF, and we believe that Yuyuan is well-positioned to further investigate.”